Orchard Therapeutics PLC (ORTX)
Stock Price:
$4.20 USD
-0.09 (-2.10%)
Updated Oct 28, 2020 12:05 PM EDT - Market open
Key Info
| Market Cap |
409.82M |
| Revenue (ttm) |
3.11M |
| Net Income (ttm) |
-180.22M |
| Shares Out |
97.58M |
| EPS (ttm) |
-1.83 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 28, 2020 |
| Last Price |
$4.20 |
| Previous Close |
$4.29 |
| Change ($) |
-0.09 |
| Change (%) |
-2.10% |
| Day's Open |
4.25 |
| Day's Range |
4.07 - 4.26 |
| Day's Volume |
236,835 |
| 52-Week Range |
3.83 - 15.93 |
More Stats
| Market Cap |
409.82M |
| Enterprise Value |
224.88M |
| Earnings Date (est) |
Nov 4, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
97.58M |
| Float |
84.01M |
| EPS (basic) |
n/a |
| EPS (diluted) |
-1.83 |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
3.28M |
| Short Ratio |
4.68 |
| Short % of Float |
3.90% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
131.78 |
| PB Ratio |
1.94 |
| Revenue |
3.11M |
| Operating Income |
n/a |
| Net Income |
-180.22M |
| Free Cash Flow |
n/a |
| Net Cash |
184.94M |
| Net Cash / Share |
1.90 |
| Gross Margin |
54.92% |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-27.76% |
| ROE |
-60.26% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (8)
| Buy |
8 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$14.50*
(245.24% upside)
Low
9.00
Current: $4.20
High
20.00
Target: 14.50
*Average 12-month price target from 8 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | 2.51 | 2.08 | - | - |
| Revenue Growth | 21.05% | - | - | - |
| Gross Profit | 1.71 | 1.65 | - | - |
| Operating Income | -173 | -235 | -38.51 | -19.20 |
| Net Income | -163 | -230 | -39.74 | -19.09 |
| Shares Outstanding | 93.24 | 22.56 | 8.87 | 7.10 |
| Earnings Per Share | -1.75 | -10.22 | -4.48 | -2.69 |
| Operating Cash Flow | -166 | -97.54 | -32.49 | -14.57 |
| Capital Expenditures | -4.37 | -4.03 | -1.56 | -0.19 |
| Free Cash Flow | -170 | -102 | -34.05 | -14.76 |
| Cash & Equivalents | 329 | 336 | 89.86 | 3.50 |
| Total Debt | 45.91 | - | - | 1.40 |
| Net Cash / Debt | 283 | 336 | 89.86 | 2.10 |
| Assets | 399 | 366 | 97.29 | 4.28 |
| Liabilities | 100 | 54.70 | 10.89 | 3.84 |
| Book Value | 299 | 311 | 86.41 | -16.52 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Orchard Therapeutics PLC |
| Country |
United Kingdom |
| Employees |
252 |
| CEO |
Bobby Gaspar |
Stock Information
| Ticker Symbol |
ORTX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ORTX |
| IPO Date |
October 31, 2018 |
Description
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-201 for mucopolysaccharidosis type MPS-IIIA and OTL-202 for mucopolysaccharidosis type IIIB. Orchard Therapeutics plc entered into a manufacturing and technology development agreement with MolMed S.p.A. to develop, manufacture and supply certain viral vectors and conduct cell processing activities for certain Orchard development and commercial programs. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is based in London, the United Kingdom.